|4Feb 11, 9:03 AM ET

ARCH Venture Partners IX, LLC 4

4 · Beam Therapeutics Inc. · Filed Feb 11, 2020

Insider Transaction Report

Form 4
Period: 2020-02-10
Transactions
  • Conversion

    Common Stock

    2020-02-10+4,121,5194,121,519 total(indirect: See footnote)
  • Conversion

    Series A-1 Preferred Stock

    2020-02-101,338,0000 total(indirect: See footnote)
    Common Stock (1,338,000 underlying)
  • Conversion

    Series A-1 Preferred Stock

    2020-02-101,338,0000 total(indirect: See footnote)
    Common Stock (1,338,000 underlying)
  • Conversion

    Series A-2 Preferred Stock

    2020-02-102,750,3360 total(indirect: See footnote)
    Common Stock (2,750,336 underlying)
  • Conversion

    Series A-2 Preferred Stock

    2020-02-102,750,3350 total(indirect: See footnote)
    Common Stock (2,750,335 underlying)
  • Conversion

    Series B Preferred Stock

    2020-02-1033,1840 total(indirect: See footnote)
    Common Stock (33,184 underlying)
  • Conversion

    Common Stock

    2020-02-10+4,121,5204,121,520 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2020-02-1033,1840 total(indirect: See footnote)
    Common Stock (33,184 underlying)
Footnotes (3)
  • [F1]Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series B Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock, Series A-2 Preferred Stock, or Series B Preferred Stock.
  • [F2]These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
  • [F3]These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION